Adamis Pharmaceuticals (ADMP) Stock Climbs On Launch News

Adamis Pharmaceuticals ADMP Stock News

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) is making a run for the top in the market after announcing an update surrounding the commercial launch of SYMJEPI, the company’s alternative to the popular EpiPen. With the positive news in mind, the sotck is climbing on gains of more than 10% so far this morning. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ADMP Stock Gains On Commercialization Update

Adamis Pharmaceuticals issued a press release early this morning, informing investors with regard to its commercial activities surrounding SYMJEPI. In the release, the company said that Sandoz, a division of Novartis (NVS), announced the US retail launch of the treatment.

The launch includes both 0.3 mg and 0.15 mg injections. These doses cover both adult and pediatric doses, which Sandoz is making immediately available in the United States.

In the release, ADMP said that Sandoz launched the 0.3 mg dose in the institutional channel earlier this year. As a result, large wholesaler customers of Sandoz are already fully stocked and ready to supply hospitals and clinics in the United States. Sandoz has also rolled out the following in order to support the commercial launch:

  • A social media program that is designed to increase awareness among both patients and their physicians.
  • The company also launched The website provides an instructional video and additional information on the product.
  • Sandoz also launched a demonstration device that simulates the use of the product.
  • A savings program has been launched, giving some patients access at zero cost.
  • The company also launched a campaign that is designed to educate hospitals and physicians with regard to writing prescriptions for the drug.
  • Finally, the company launched a lobbying initiative that is designed to modify existing state legislation to increase the avialability of epinephrine in schools.

In a statement, Dr. Dennis J. Carlo, President and CEO at ADMP, had the following to offer:

Along with Sandoz, Adamis is thrilled to bring broad access to this critical medicine for patients. We expect that SYMJEPI will play a role in ending the chronic shortages of epinephrine injection products in the U.S.

This News Is Huge!!!

At the end of the day, the launch of SYMJEPI is great news for Adamis Pharmaceuticals and its investors. The company’s commercialization partner, Novartis, parent to Sandoz, is no stranger to turning effective treatments into blockbuster treatments. Given the activities taking place to date, I believe that SYMJEPI has a real chance of becoming one of these treatments, throwing a wrench in the EpiPen’s leadership in the sector.

Considering potential milestone payments and royalties to come, and the fact that ADMP has a market cap of just over $69 million, the opportunity for growth here is tremendous!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Never miss the news again! Join our FREE mailing list below!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.